Eli Lilly’s and Regeneron’s mAb EUA Talk Trigger Expert Prudence on Available COVID-19 Data; Clinical Trials Likely to Be Affected if EUAs Come Through
October 9, 2020
Manasi Vaidya
GlobalData
Axinn partner Chad Landmon was quoted in the GlobalData article, "Eli Lilly’s and Regeneron’s mAb EUA Talk Trigger Expert Prudence on Available COVID-19 Data; Clinical Trials Likely to Be Affected if EUAs Come Through."
Click here to access the article with the permission of “Investigative News team at GlobalData."